NASDAQ:MYL - Mylan Stock Price, Price Target & More

Question 1

What is Mylan's stock symbol?

Answer

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Question 2

How were Mylan's earnings last quarter?

Answer

Mylan NV (NASDAQ:MYL) posted its quarterly earnings results on Wednesday, May, 9th. The company reported $0.96 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.99 by $0.03. The business earned $2.68 billion during the quarter, compared to analyst estimates of $2.74 billion. Mylan had a net margin of 6.04% and a return on equity of 18.56%. The firm's quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.93 earnings per share. View Mylan's Earnings History.

Question 3

When is Mylan's next earnings date?

Answer

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Mylan.

Question 4

What guidance has Mylan issued on next quarter's earnings?

Answer

Mylan issued an update on its FY18 earnings guidance on Wednesday, May, 9th. The company provided earnings per share guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.37. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.

Question 5

What price target have analysts set for MYL?

Answer

19 brokers have issued 1 year price targets for Mylan's shares. Their predictions range from $29.39 to $59.00. On average, they anticipate Mylan's share price to reach $46.7047 in the next twelve months. This suggests a possible upside of 31.5% from the stock's current price. View Analyst Ratings for Mylan.

Question 6

What is the consensus analysts' recommendation for Mylan?

Answer

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Question 7

What are Wall Street analysts saying about Mylan stock?

Answer

Here are some recent quotes from research analysts about Mylan stock:

1. Guggenheim analysts commented, "We spoke with two oncologists in different practice settings regarding their potential use of Fulphila. While biosimilar financial incentives will play a role in Fulphila’s adoption, the Onpro device appears entrenched in current clinical practice. For that and other reasons, we believe that it might be more prudent to take a conservative approach to Fulphila’s uptake at the outset. We maintain our BUY rating on shares of Mylan. Consultant Commentary: We spoke with two oncologists on their respective academic and rural private practice settings. The academic consultant saw roughly 100 Neulasta patients per month while the rural oncologist saw ~30 Neulasta patients per month." (6/14/2018)
2. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) The North America segment was down 8%, excluding Epipen, which declined $131.9MM in 4Q17, and $655.4MM in 2017. EU grew 16% in the quarter, and Rest of World grew 12%. 2) Generic drug pricing continued to be a headwind in the U.S. during the quarter. However, favorable pricing on existing products in Europe was a tailwind in 4Q17. 3) The Restasis target action date is in July 2018. The Biosimilar pegfilgrastim target action date is in early June. 4) MYL repurchased 12.4MM shares during 2017, and an additional 9.8MM shares in January 2018. 4) MYL expects to launch generic Adavir and Neulasta in 2018, and has risk-weighted these launches in its 2018 guidance." (3/1/2018)
3. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
4. Argus analysts commented, "junior version" (8/22/2017)

Question 8

Are investors shorting Mylan?

Answer

Mylan saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 11,394,932 shares, a decrease of 33.0% from the June 15th total of 17,000,496 shares. Based on an average daily volume of 3,875,140 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.3% of the company's stock are sold short. View Mylan's Current Options Chain.

Question 9

Who are some of Mylan's key competitors?

Answer

Some companies that are related to Mylan include Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS) and Merck KGaA (MKGAF).

Question 10

Who are Mylan's key executives?

Answer

Mylan's management team includes the folowing people:

Ms. Heather Bresch, CEO & Exec. Director (Age 49)
Mr. Rajiv Malik, Pres & Exec. Director (Age 57)
Mr. Kenneth S. Parks, Chief Financial Officer (Age 55)
Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 45)
Mr. Anthony Mauro, Chief Commercial Officer (Age 45)

Question 11

Has Mylan been receiving favorable news coverage?

Answer

Media coverage about MYL stock has trended positive on Saturday, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mylan earned a media sentiment score of 0.26 on Accern's scale. They also gave media coverage about the company an impact score of 44.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Question 12

Who are Mylan's major shareholders?

Answer

Mylan's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Hexavest Inc. (0.28%), Retirement Systems of Alabama (0.08%), Assenagon Asset Management S.A. (0.07%), Bank of Montreal Can (0.06%), Kirr Marbach & Co. LLC IN (0.04%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan.

Question 13

Which institutional investors are selling Mylan stock?

Answer

MYL stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, LS Investment Advisors LLC, Hartford Investment Management Co., Nisa Investment Advisors LLC, Gateway Investment Advisers LLC and Kirr Marbach & Co. LLC IN. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

Question 14

Which institutional investors are buying Mylan stock?

Answer

MYL stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Retirement Systems of Alabama, Highland Capital Management LLC, Clinton Group Inc., Fox Run Management L.L.C., Jabodon PT Co., Fjarde AP Fonden Fourth Swedish National Pension Fund and Cornerstone Wealth Management LLC. View Insider Buying and Selling for Mylan.

Question 15

How do I buy shares of Mylan?

Answer

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 16

What is Mylan's stock price today?

Answer

One share of MYL stock can currently be purchased for approximately $35.53.

Question 17

How big of a company is Mylan?

Answer

Mylan has a market capitalization of $18.37 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

Question 18

How can I contact Mylan?

Answer

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		606 (Vote Outperform)
Underperform Votes:		451 (Vote Underperform)
Total Votes:		1,057

NASDAQ:MYL - Mylan Stock Price, Price Target & More

Receive MYL News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Mylan (NASDAQ:MYL) Frequently Asked Questions